Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients

Clinical Chemistry

Volumn 42, Issue 9, 1996, Pages 1426-1432

  Gonschior, Ann Katrin ^a   Christians, Uwe ^c   Winkler, Michael ^b   Linck, Annette ^a   Baumann, Jana ^b   Sewing, Karl Friedrich ^a  

^a Inst F Allgemeine Pharmakologie   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

high performance liquid chromatography; immunosuppressants; macrolides; mass spectrometry; metabolism; microparticle enzyme immunoassay; organ transplantation; therapeutic drug monitoring

Indexed keywords

DRUG METABOLITE; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; STATISTICAL ANALYSIS;

EID: 0029783338     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.9.1426     Document Type: Article

References (32)

1. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramanan R, Jain A. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989;ii:1000-4.
2. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus: a review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
3. Abu-Elmagd K, van Thiel D, Jegasothy B, Ackerman CD, Todo S, Fung J, et al. FK506: a new therapeutic agent for severe recalcitrant psoriasis. Transplant Proc 1991;3:3322-4.
4. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
5. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK 506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
6. Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, et al. FK506 in clinical kidney transplantation. Transplant Proc 1991;23:3065-7.
7. Devlin J, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, et al. Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. Transplant Int 1994;7(Suppl 1):22-6.
8. Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Williams R, et al. Neurological complications in the European multicentre study of FK506 and cyclosporin in primary liver transplantation. Transplant Int 1994;7(Suppl 1):27-31.
9. Ericzon B, Groth C, Bismuth H, Calne R, McMaster P, Neuhaus P, et al. Glucose metabolism in liver transplant recipients treated with FK506 or cyclosporin in the European multicentre study. Transplant Int 1994;7(Suppl 1):11-4.
10. Alessiani M, Cillo U, Fung J, Irish W, Abu-Elmagd K, Jain A, et al. Adverse effects of FK506 overdosage after liver transplantation. Transplant Proc 1993;25:628-34.
11. Shiraga T, Matsuda H, Nagase K, Iwasaki K, Noda K, Yamazaki H, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994;47:727-35.
12. Sattler M, Guengerich F, Yun CH, Christians U, Sewing KF. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
13. Vincent S, Karanam B, Painter S, Chiu SHL. In vitro metabolism of FK506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 1992;294:454-60.
14. Christians U, Kruse C, Kownatzki R, Schiebel HM, Schwinzer R, Sattler M, et al. Measurement of FK506 by HPLC and isolation and characterization of its metabolites. Transplant Proc 1991;23: 940-1.
15. Christians U, Braun F, Kosian N, Schmidt M, Schiebel HM, Ernst L, et al. High performance liquid chromatography/mass spectrometry of FK506 and its metabolites in blood, bile and urine of liver grafted patients. Transplant Proc 1991;23:2741-4.
16. Christians U, Braun F, Schmidt M, Kosian N, Schiebel HM, Ernst L, et al. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients. Clin Chem 1992;38:2025-32.
17. Kobayashi M, Tamura K, Katayama N, Nakamura K, Nagase K, Hane K, et al. FK506 assay past and present - characteristics of FK506 ELISA. Transplant Proc 1991;23:2725-9.
18. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, et al. A whole blood FK506 assay for the IMx® analyzer. Transplant Proc 1991;23:2748-9.
19. Winkler M, Ringe B, Christians U, Sewing KF, Wonigeit K, Pichlmayr R. Therapeutic drug monitoring in patients under FK506 immunosuppression. Klin Lab 1994;40:1-6.
20. Iwasaki K, Shiraga T, Nagase K, Tozuka Z, Noda K, Sakuma S, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 1993;21:971-7.
21. Iwasaki K, Shiraga T, Matsuda H, Nagase K, Tokuma Y, Hata T, et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. Drug Metab Dispos 1995;23:28-34.
22. Gonschior AK, Christians U, Winkler M, Schiebel HM, Linck A, Sewing KF. Simplified high-performance liquid chromatography-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross-validation with microparticle enzyme immunoassay. Ther Drug Monit 1995;17:504-10.
23. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
24. Hebert M, Roberts J, Prueksaritanont T, Benet L. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
25. Stolz A, Kaplowitz N. Biochemical tests for liver disease. In: Zakim D, Boyer TD, eds. Hepatology, a textbook of liver disease. Philadelphia: WB Saunders Co, 1990:637-67.
26. Kohlhaw K, Christians U, Sürig T, Lamesch P, Hauss J, Sewing KF, Pichlmayr R. Cyclosporine and bilirubin metabolites compete for the hepatic excretory system. Transplant Proc 1994;26:2798-9.
27. Christians U, Spiekermann K, Bader A, Schottmann R, Linck A, Wonigeit K, et al. Cyclosporine metabolite pattern in blood from patients with acute GVHD after BMT. Bone Marrow Transplant 1993;12:27-33.
28. Bleck J, Schlitt H, Christians U, Schottmann R, Thiesemann C, Strohmeyer S, et al. Ciclosporin metabolite pattern in blood and urine of kidney graft patients in relation to liver function. Eur J Clin Pharmacol 1991;40:565-9.
29. Winkler M, Christians U, Stoll K, Baumann J, Pichlmayr R. Comparison of different assays for the quantitation of FK506 levels in blood or plasma. Ther Drug Monit 1994;16:281-6.
30. Abu-Elmagd K, Fung J, Alessiani M, Jain A, Venkataramanan R, Warty V, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991;52:71-7.
31. Winkler M, Christians U, Gonschior AK, Baumann J, Kattner A, Wonigeit K. Evaluation of the new Pro-TracR tacrolimus monoclonal whole blood ELISA for monitoring of tacrolimus levels in patients after kidney, heart and liver transplantation [abstract]. Ther Drug Monit 1995;17:430.
32. Abu-Elmagd K, Fung J, Alessiani M, Jain A, Venkataramanan R, Warty V, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991;52:71-7.